References
- Lowe K. C. Perfluorochemicals in vascular medicine. Vase. Med. Rev. 1994; 5: 15–32
- Zuck T. F., Riess J. G. Current status of injectable oxygen carriers. Cril. Rev. Clin. Lab. Sci. 1994; 31: 295–324
- Lowe K. C. Perfluorochemical respiratory gas carriers: applications in medicine and biotechology. Science Prog. 1997; 80: 169–193
- Gershlick A. H., Spriggins D., Davies S. W., Syndercombe Court Y. D., Timmins J., Timmis A. D., Rothman M. T., Layton C., Balcon R. Failure of Epoprostanol (prostacyclin, POI2) to inhibit platelet-aggregation and to prevent restenosis after coronary angioplasty. Results of a randomised placebo-controlled trial. Br. Heart J. 1995; 71: 7–15
- Armstrong J. K., Meiselman H. J., Fisher T. C. Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx Injection). Thromb. Res. 1995; 79: 437–450
- Edwards CM., May J. A., Heptinstall S., Lowe K. C. Effects of Pluronic F-68 (Poloxamer 188) on platelet aggregation in human whole blood. Thromb. Res. 1996; 81: 511–512
- Edwards CM., Heptinstall S., Lowe K. C. Effects of the copolymer surfactant, Pluronic F-68, on platelet aggregation in human whole blood. Art. Cells, Blood Subs., and Immob. Biotech. 1997; 25, in press
- Snedecor G. W., Cochran W. G. Statistical Methods8th Edn. Iowa State College Press, Ames 1989
- Schmolka I. R. Physical basis for poloxamer interactions. Ann. N.Y. Acad. Sci. 1994; 720: 92–97
- Colbassani H. J., Barrow D. L., Sweeney K. M., Kakay R. A.E., Check I. J., Hunter R. L. Modification of acute focal ischemia in rabbits by poloxamer 188. Stroke 1989; 20: 1241–1246
- Smith CM., Hcbbel R. P., Tukey DP., Clawson C.C., White J. G., Vercellotti C, Pluronic M. F. -68 reduces the endothelial adherence and improves the rhcology of liganded sickle erythrocytes. Blood 1987; 69: 1631–1636
- Carter C, Fisher T.C., Hamai H., Johnson C. S., Meiselman H. J., Nash G. B., Stuart J. Haemorheological effects of a nonionic copolymer surfactant (Poloxamer 188). Clin. Hemorheol. 1992; 12: 109–120
- Papoutsakis E. T. Fluid mechanical damage of animal cells in bioreactors. Trends Biotechnol. 1991; 9: 427–437
- Wu J. Mechanisms of animal cell damage associated with gas bubbles and cell protection by medium additives. J. Biotechnol. 1995; 43: 81–94
- Markwardt F. The development of hirudin as an antithrombotic drug. Thromb. Res. 1994; 74: 1–23
- Schaer G. L., Hursey T. L., Abrahams S. L., Buddemeier K., Ennis B., Rodriguez R., Hubbell J. P., Moy J., Parrillo J. E. Reduction in reperfusion-induced myocardial injury in dogs by RheothRx Injection (Poloxamer 188 N.F.), a hemorhcological agent that alters neutrophil function. Circulation 1994; 90: 2964–2975
- Hunter R. L., Bennett B., Check I. J. The effect of poloxamcr 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase. Fibrinolysis 1990; 4: 117–123
- Edwards CM, Lowe K. C., Trabelsi H., Lucas P., Cambon A. Novel fluorinated surfactants for perfluorochemical emulsification: biocompatibility assessments of glycosidic and polyol derivatives. An. Cells, Blood Subs., and Immob. Biotech. 1997; 25: 27–333